| CAS | 204318-14-9 |
| Sequence | 4,7,10-Tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-L-threoninol (Disulfide bond) |
| Sequence Single | 4,7,10-Tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl-fCYwKTC-L-threoninol |
| Molecular Formula | C65H92N14O18S2 |
| Molecular Weight | 1421.66 |
| Synonyms | DOTATOC, Edotreotide |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Cancer Research |
| Description | DOTA-(Tyr3)-Octreotide also called DOTATOC, Edotreotide, is a somatostatin analogue. DOTA-(Tyr3)-Octreotide bound to various radionuclides, has the potential for the research and diagnosis of certain types of cancer. |
| References | 1. Immunogenicity and bioactivity of glucagon, modified at methionine-27. W.J.Nooijen and H.J.Kempen, Horm. Metab. Res., 11, 459 (1979) 2. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Norenberg JP, et al. Clin Cancer Res. 2006;12(3 Pt 1):897-903. |